サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1783997

転移性肺腺がんの治療の世界市場

Metastatic Lung Adenocarcinoma Treatment

出版日
ページ情報
英文 286 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
転移性肺腺がんの治療の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

転移性肺腺がんの治療の世界市場は2030年までに86億米ドルに達する

2024年に48億米ドルと推定される転移性肺腺がんの治療の世界市場は、2024～2030年の分析期間においてCAGR 10.5%で成長し、2030年には86億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 8.3%を記録し、分析期間終了時には26億米ドルに達すると予測されます。標的療法分野の成長率は、分析期間でCAGR 12.5％と推定されます。

米国市場は13億米ドルと推定、中国はCAGR13.9％で成長予測

米国の転移性肺腺がんの治療市場は、2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.7%と9.1%と予測されています。欧州では、ドイツがCAGR約8.2%で成長すると予測されています。

世界の転移性肺腺がんの治療市場- 主要動向と促進要因まとめ

転移性肺腺がんとは何か、どのように治療されるのか？

転移性肺腺がんは非小細胞肺がん（NSCLC）の末期型で、肺に発生したがんが脳、骨、肝臓、副腎などの遠隔臓器に転移します。NSCLCの最も一般的なサブタイプであり、肺がん症例全体の40～50％近くを占める。この病期では特に侵攻性が強く、多くの場合、手術や放射線治療などの局所的治療ではなく、全身療法を含む多剤併用療法が必要となります。転移性症例の主な治療目標は、疾患の進行を遅らせ、生存期間を延長し、患者のQOLを改善または維持することです。

治療戦略は高度に個別化され、腫瘍の分子および遺伝子プロファイリングによって導かれることが多くなっています。標的治療薬、免疫チェックポイント阻害薬、先進的化学療法レジメンが現代の治療計画の中核をなしています。EGFR、ALK、ROS1、BRAFのような特定の変異を標的とする薬剤は、より高い奏効率と無増悪生存期間の延長をもたらし、患者のサブセットの転帰を大きく変えました。免疫療法、特にPD-1阻害剤とPD-L1阻害剤も、単独または化学療法との併用で、特に実用的な変異のない患者に対する最前線の治療法として台頭してきました。腫瘍生物学の理解が深まるにつれて、治療プロトコールは患者固有の特徴に合わせて絶えず進化しています。

技術的および臨床的進歩に伴い、市場はどのように進化しているか？

転移性肺腺がんの治療状況は、プレシジョン・オンコロジー、コンパニオン・ダイアグノスティックス、薬剤開発におけるブレークスルーに牽引され、過去10年間でパラダイムシフトを遂げてきました。リキッドバイオプシーと次世代シークエンシング（NGS）技術の出現により、腫瘍医は実用的な遺伝子変化を非侵襲的に検出できるようになり、タイムリーで正確な治療法の選択が可能になりました。これらの技術革新により、治療までの時間が短縮され、進行の早い転移性疾患を管理する上で重要な要素である、効果のない治療のリスクが最小限に抑えられています。

これと並行して、医薬品のパイプラインも急速に拡大し、より広範な分子変異を標的とする数多くの新規薬剤が、現在後期臨床試験段階にあるか、最近承認されました。KRAS G12C阻害剤、MET阻害剤、RET融合標的薬などの薬剤は、個別化治療に新たな局面をもたらしています。さらに、免疫チェックポイント阻害剤と抗血管新生剤や化学療法との組み合わせなどの併用戦略は、臨床試験で全生存期間の改善を示しており、標準治療のアルゴリズムを再構築しています。市場はまた、腫瘍微小環境調節薬やT細胞エンゲイジャーへの関心が高まっており、治療が変異特異的であるだけでなく免疫学的反応と深く統合されたものになる未来を示唆しています。

転移性肺腺がんの治療市場の成長はいくつかの要因によってもたらされる

転移性肺腺がんの治療市場の開拓はいくつかの要因によって推進されています。主な要因としては、世界の肺がん罹患率の増加、特に高齢化社会と発展途上地域の喫煙者における肺がん罹患率の増加が挙げられます。認知度の向上、スクリーニングプログラムの改善、診断インフラの改善により、転移がより正確かつ早期に発見されるようになり、高度な全身療法の対象となる患者層が拡大しています。さらに、肺がん患者の割合が増加している中で実用的な遺伝子変異が同定されたことにより、標的治療がより広範に適用されるようになり、プレシジョンメディシンの技術革新と普及の両方が促進されています。

診断ツールの技術的進歩、特にリキッドバイオプシーと包括的ゲノムプロファイリングの急速な導入は、より個別化された治療レジメンを促進し、患者の転帰を改善しています。加えて、米国、欧州、中国などの主要市場では、規制の枠組みが整備され、承認が加速しているため、革新的ながん治療薬の市場参入が加速しています。バイオ医薬品企業による研究開発への旺盛な投資、学界と産業界との協力関係の強化、新興国におけるヘルスケア適用範囲の拡大も、市場拡大に寄与しています。これらの要因が相まって、世界の転移性肺腺がん領域では、より効果的で毒性が低く、患者中心の治療ソリューションに対する需要が高まっています。

セグメント

治療（化学療法、標的療法、免疫療法、放射線療法、その他）、エンドユーザー（病院、専門クリニック、その他）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Summit Therapeutics
  • Takeda Pharmaceutical Company

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32121

Global Metastatic Lung Adenocarcinoma Treatment Market to Reach US$8.6 Billion by 2030

The global market for Metastatic Lung Adenocarcinoma Treatment estimated at US$4.8 Billion in the year 2024, is expected to reach US$8.6 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 13.9% CAGR

The Metastatic Lung Adenocarcinoma Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 9.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Metastatic Lung Adenocarcinoma Treatment Market - Key Trends & Drivers Summarized

What is Metastatic Lung Adenocarcinoma and How is It Treated?

Metastatic lung adenocarcinoma is a late-stage form of non-small cell lung cancer (NSCLC), where the cancer originating in the lungs spreads (metastasizes) to distant organs such as the brain, bones, liver, or adrenal glands. It is the most common subtype of NSCLC, accounting for nearly 40-50% of all lung cancer cases. The disease is particularly aggressive at this stage and often requires a multimodal treatment approach that includes systemic therapies rather than localized interventions such as surgery or radiotherapy. The primary treatment goals for metastatic cases are to slow disease progression, prolong survival, and improve or maintain the patient’s quality of life.

Treatment strategies are highly individualized and increasingly guided by molecular and genetic profiling of tumors. Targeted therapies, immune checkpoint inhibitors, and advanced chemotherapy regimens form the core of contemporary treatment plans. Drugs that target specific mutations such as EGFR, ALK, ROS1, and BRAF have significantly changed outcomes for subsets of patients, offering higher response rates and extended progression-free survival. Immunotherapies-particularly PD-1 and PD-L1 inhibitors-have also emerged as frontline treatments, either alone or in combination with chemotherapy, especially for patients without actionable mutations. As understanding of tumor biology deepens, treatment protocols are continuously evolving to align with patient-specific characteristics.

How is the Market Evolving with Technological and Clinical Advancements?

The treatment landscape for metastatic lung adenocarcinoma has undergone a paradigm shift over the past decade, driven by breakthroughs in precision oncology, companion diagnostics, and drug development. The emergence of liquid biopsies and next-generation sequencing (NGS) technologies has enabled oncologists to detect actionable genetic alterations non-invasively, allowing for timely and accurate therapy selection. These innovations are reducing the time to treatment and minimizing the risk of ineffective therapies, a critical factor in managing fast-progressing metastatic disease.

In parallel, the pharmaceutical pipeline has expanded rapidly, with numerous novel agents targeting a wider range of molecular mutations currently in late-stage clinical trials or recently approved. Agents like KRAS G12C inhibitors, MET inhibitors, and RET fusion-targeting drugs are adding new dimensions to personalized treatment. Furthermore, combination strategies-such as pairing immune checkpoint inhibitors with anti-angiogenic agents or chemotherapy-are demonstrating improved overall survival in clinical trials, reshaping standard-of-care algorithms. The market is also seeing increasing interest in tumor microenvironment modulation and T-cell engagers, pointing to a future where treatment is not only mutation-specific but also deeply integrated with immunologic responses.

The Growth in the Metastatic Lung Adenocarcinoma Treatment Market is Driven by Several Factors

The growth in the metastatic lung adenocarcinoma treatment market is driven by several factors, primarily the increasing global incidence of lung cancer, particularly in aging populations and among smokers in developing regions. Rising awareness, improved screening programs, and better diagnostic infrastructure are leading to more accurate and earlier detection of metastasis, thereby expanding the pool of patients eligible for advanced systemic therapies. Moreover, the identification of actionable genetic mutations in a growing proportion of lung cancer patients has enabled targeted therapy to be applied more broadly, driving both innovation and uptake of precision medicines.

Technological advancements in diagnostic tools, especially the rapid adoption of liquid biopsies and comprehensive genomic profiling, are facilitating more personalized treatment regimens and improving patient outcomes. In addition, favorable regulatory frameworks and accelerated approval pathways in key markets such as the U.S., Europe, and China are enabling faster market entry for innovative oncology drugs. Strong investment from biopharmaceutical companies in R&D, increasing collaboration between academia and industry, and expanding healthcare coverage in emerging economies are also contributing to market expansion. Collectively, these drivers are fueling the demand for more effective, less toxic, and patient-centric treatment solutions in the global metastatic lung adenocarcinoma space.

SCOPE OF STUDY:

The report analyzes the Metastatic Lung Adenocarcinoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Others); End-Use (Hospitals, Specialty Clinics, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Summit Therapeutics
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Metastatic Lung Adenocarcinoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Non-Small Cell Lung Cancer Propels Demand for Advanced Therapeutics
    • Growing Emphasis on Precision Medicine Strengthens Business Case for Targeted Therapies
    • Increased Adoption of Next-Generation Sequencing (NGS) Drives Demand for Companion Diagnostics
    • Expanding Use of Biomarker-Based Stratification Expands Addressable Market Opportunity
    • Breakthroughs in Immunotherapy Accelerate Demand for Checkpoint Inhibitors
    • Expanding FDA Approvals for Targeted Therapies Spurs Growth in Treatment Options
    • Integration of AI in Drug Discovery Throws the Spotlight on Personalized Treatment Pathways
    • Rising Government and Private Sector Funding Supports Innovation in Oncology Research
    • Shift Toward Outpatient and Home-Based Cancer Care Models Drives Adoption of Oral Therapies
    • Increasing Use of Real-World Evidence (RWE) Strengthens Business Case for Therapy Reimbursement
    • Growing Demand for Minimal Side-Effect Profiles Propels Development of Novel Drug Delivery Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metastatic Lung Adenocarcinoma Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Metastatic Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metastatic Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Metastatic Lung Adenocarcinoma Treatment by End-Use - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Metastatic Lung Adenocarcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION